



Drug Enforcement Administration

[Docket No. DEA-810]

Importer of Controlled Substances Application: Royal Emerald Pharmaceuticals

Research and Development DBA: Royal Emerald Pharmaceuticals

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Royal Emerald Pharmaceuticals Research and Development DBA: Royal Emerald Pharmaceuticals has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before **[INSERT 30 DAYS AFTER PUBLICATION IN THE FEDERAL REGISTER]**. Such persons may also file a written request for a hearing on the application on or before **[INSERT 30 DAYS AFTER PUBLICATION IN THE FEDERAL REGISTER]**.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on May 22, 2020, Royal Emerald Pharmaceuticals Research and Development DBA: Royal Emerald Pharmaceuticals, 14011 Palm Drive, Desert Hot Springs, California 92240, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled Substance	Drug Code	Schedule
Marihuana	7360	I
Tetrahydrocannabinols	7370	I

The company plans to import Marihuana seeds and immature Marihuana plants in the form of Active Pharmaceutical Ingredients (API) and botanical raw materials for DEA-approved legitimate scientific medical research and/or industrial purposes.

William T. McDermott,

Assistant Administrator.

[FR Doc. 2021-06900 Filed: 4/2/2021 8:45 am; Publication Date: 4/5/2021]